Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
NXP800
i
Other names:
NXP800, NXP 800, NXP-800, CCT361814, CCT 361814, CCT-361814
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(5)
News
Trials
Company:
Cancer Therapeutics CRC, Nuvectis Pharma
Drug class:
GCN2 activator
Related drugs:
‹
HC-7366 (1)
DP-9149 (0)
HC-7366 (1)
DP-9149 (0)
›
Associations
(5)
News
Trials
VERI cancer hierarchy
Reset Filters
ARID1A mutation
Ovarian Cancer
ARID1A mutation
Ovarian Cancer
NXP800
Sensitive: B - Late Trials
NXP800
Sensitive
:
B
NXP800
Sensitive: B - Late Trials
NXP800
Sensitive
:
B
AR overexpression
Cholangiocarcinoma
AR overexpression
Cholangiocarcinoma
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
NRAS Q61
Cholangiocarcinoma
NRAS Q61
Cholangiocarcinoma
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
FGFR2 overexpression
Cholangiocarcinoma
FGFR2 overexpression
Cholangiocarcinoma
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
FGFR1 overexpression
Cholangiocarcinoma
FGFR1 overexpression
Cholangiocarcinoma
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
NXP800
Sensitive: D – Preclinical
NXP800
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login